Compare ADMA Biologics Inc (ADMA) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs LTC Properties Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while LTC Properties Inc trades at $39.24 (market cap $2.01B). The key difference: ADMA Biologics Inc and LTC Properties Inc are close in size by market cap, and LTC Properties Inc pays a 5.81% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LTC | |
|---|---|---|
Market Cap | $2.13B | $2.01B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $40.36 |
52-Week Low | $7.60 | $33.98 |
Enterprise Value | $2.20B | $2.86B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
LTC Properties trades at $39.23, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.69, missing expectations of $0.72, but revenue grew to $263M in 2025. Analyst consensus is mixed with 27% buy ratings, while recent news highlights dividend declarations and a $54M SHOP acquisition, reinforcing its focus on senior housing investments.
Outlook remains supported by demographic trends in senior housing, though earnings misses and high debt levels pose risks. The stock offers a monthly dividend, but investors face headwinds from execution challenges in shifting to SHOP strategy and interest rate sensitivity due to substantial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
